Introduction
============

Certain *EGFR* mutations in patients with non-small-cell lung cancer (NSCLC) are associated with acquired resistance to first-line epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs). The most common resistance-conferring mutation is T790M. Patients with this mutation often respond to the EGFR TKI known as AZD9291, so the mutation must first be confirmed through re-biopsy.[@b1-ott-10-3307]--[@b3-ott-10-3307] This normally involves re-biopsy of the tumor tissue for subsequent sequencing, but biopsy is associated with safety risks and pain.

Blood biopsy has been proposed as a less risky and painful alternative. Blood contains circulating tumor DNA (ctDNA) within tumor cells as well as circulating free DNA.[@b4-ott-10-3307] These DNA can then be sequenced. New techniques with higher sensitivity (eg, droplet digital PCR \[ddPCR\]), compared with conventional amplification refractory mutation system (ARMS), show promising results while testing ctDNA, but the positive rates are still quite varied and unclear.[@b5-ott-10-3307]--[@b9-ott-10-3307] This forces blood biopsy by ctDNA to be an alternative approach,[@b10-ott-10-3307] and tissue-based molecular analysis remains the recommended standard for evaluating resistance to TKIs.[@b11-ott-10-3307] Finding out the factors affecting the performance and reliability of the tests is necessary for the optimization of blood biopsy by ctDNA. Other factors that affect the tests, except technology, are still unclear.

Here, we genotyped *EGFR* from either tissue or blood biopsy samples for detecting various *EGFR* mutations linked to TKI resistance in patients with NSCLC. In particular, we focused on the mutation T790M. DNA extracted from both types of biopsies was sequenced using the conventional ARMS. We chose this system for two reasons: first, it is still the standard system used for tissue biopsy at our hospital; second, we wanted to know whether there are other factors, except technology, affecting the results. The findings of this study may shed light on the optimization of the performance and reliability of blood biopsy, especially relative to tissue biopsy, for diagnosing acquired EGFR TKI resistance associated with T790M.

Materials and methods
=====================

Study design
------------

This observational study was conducted on patients treated at West China Hospital (Chengdu, People's Republic of China) between 2014 and 2016. Patients were eligible if they had advanced NSCLC involving *EGFR* mutation(s), were clinically resistant to EGFR TKIs (gefitinib, erlotinib, icotinib, or afatinib), and were undergoing re-biopsy for *EGFR* genotyping as part of their routine clinical care. The study was approved by the Biomedical Research Ethics Committee of West China Hospital of Sichuan University, and all patients signed the informed consent form.

Blood sampling and sequencing
-----------------------------

Peripheral blood was collected within 2 weeks of re-biopsy into a 10-mL vacutainer containing ethylenediaminetetraacetic acid. Blood samples were transported to our laboratory within 2 h of being drawn, plasma was isolated by centrifugation at 2,000× *g* for 10 min, and the supernatant was further cleared at 8,000× *g* for an additional 10 min. The Circulating Nucleic Acid Kit (AmoyDx, Xiamen, People's Republic of China) was used to isolate ctDNA according to the manufacturer's protocol. *EGFR* genotyping was performed on tissue biopsies according to standard institutional procedures in a certified laboratory, with conventional ARMS sequencing carried out using the Human EGFR Gene Mutations Fluorescence PCR Diagnostic Kit (AmoyDx). The same kit was used to genotype *EGFR* from ctDNA. This kit has been approved for clinical use by the China Food and Drug Administration since 2010.

Statistical analysis
--------------------

Diagnostic concordance between ARMS sequencing of tissue-derived DNA or ctDNA was assessed using Cohen's κ, and the concordance was assessed for significance using the McNemar test. Percent agreement values were calculated based on the main diagonal in 2×2 tables. All statistical analyses were performed with SPSS 20.0 (IBM Corp., Armonk, NY, USA), and the significance threshold was set as *P*\<0.05.

Results
=======

Patient characteristics
-----------------------

From January 2014 to June 2016, 45 patients were enrolled in the study ([Figure 1](#f1-ott-10-3307){ref-type="fig"}, [Table 1](#t1-ott-10-3307){ref-type="table"}). Of the 45 patients, 4 (8.9%) received two types of EGFR TKI. As the most recent treatment, 8 (17.8%) received chemotherapy, 4 (8.9%) received EGFR TKI plus chemotherapy, and 33 (73.3%) received EGFR TKI.

EGFR genotyping in tissue biopsy and plasma ctDNA
-------------------------------------------------

Among patients whose tissue biopsy was sequenced, 25 showed two *EGFR* mutations, 12 showed one mutation, and 1 had three mutations ([Table 2](#t2-ott-10-3307){ref-type="table"}). Among patients whose plasma ctDNA was sequenced, 14 had two types of *EGFR* mutation, 12 had no mutation, and 5 showed one mutation.

Of the 24 patients whose tissue and plasma ctDNA were sequenced ([Table 3](#t3-ott-10-3307){ref-type="table"}), 18 (75.0%) were concordant for exon 19 deletion (κ=0.385; [Figure 2A](#f2-ott-10-3307){ref-type="fig"}), 21 (87.5%) were concordant for L858R (κ=0.654; [Figure 2B](#f2-ott-10-3307){ref-type="fig"}), and 10 (41.7%) were concordant for T790M (κ=0.006; [Figure 2C](#f2-ott-10-3307){ref-type="fig"}).

The positive rate for T790M mutation was 70.8% based on tissue sequencing and 37.5% based on plasma ctDNA sequencing ([Table 3](#t3-ott-10-3307){ref-type="table"}). Of the 24 patients for whom both tissue and plasma ctDNA sequencing results were available, 9 (37.5%) showed the same results, although the plasma ctDNA results for one-third of these patients were only weakly positive. Of the 17 patients who were positive for T790M based on the tissue test, only 7 (41.2%) were positive for the plasma ctDNA test, and 3 of those 7 were only weakly positive. Of the 7 patients negative for T790M based on tissue sequencing, 2 were positive based on plasma ctDNA sequencing ([Table 4](#t4-ott-10-3307){ref-type="table"}).

Discussion
==========

In this study, we used conventional ARMS to sequence the *EGFR* gene of patients with NSCLC for mutations associated with TKIs resistance from re-biopsied tumor DNA or from plasma ctDNA. Our results suggest that ctDNA can be a suitable template for *EGFR* genotyping in these patients, although the positive rate for T790M (37.5%) based on blood biopsy is lower than that based on tissue sequencing (70.8%). These findings support the usefulness of plasma ctDNA for mutation analysis as established in several other disease contexts[@b9-ott-10-3307],[@b12-ott-10-3307]--[@b17-ott-10-3307] and also suggest that there are other factors affecting the performance results of the test.

We sequenced the *EGFR* gene from tissue and blood using conventional ARMS despite its lower sensitivity,[@b18-ott-10-3307] rather than using newer techniques such as ddPCR,[@b12-ott-10-3307],[@b19-ott-10-3307]--[@b21-ott-10-3307] because we wanted to analyze both types of biopsy in the same way to identify whether there are other factors, except technology, affecting the results. This should not threaten the validity of our results because studies using newer techniques also show a large variation in T790M-positive rates,[@b6-ott-10-3307]--[@b9-ott-10-3307],[@b12-ott-10-3307]--[@b15-ott-10-3307],[@b19-ott-10-3307]--[@b22-ott-10-3307] and the same held true even in four prospective studies on NSCLC patients with acquired resistance.[@b6-ott-10-3307]--[@b8-ott-10-3307],[@b23-ott-10-3307] Indeed, the fact that our T790M-positive rate based on tissue sequencing (70.8%) was similar to that of several previous studies (63%, 66%, and 76.5%)[@b6-ott-10-3307]--[@b8-ott-10-3307] suggests that our study population was representative of the target patient population.

Some important characteristics of the four prospective studies and this study are listed in [Table S1](#SD1-ott-10-3307){ref-type="supplementary-material"}. All these prospective studies used new techniques with higher sensitivity. Mok et al[@b23-ott-10-3307] used allele-specific amplification, but the kit (cobas^®^, Roche Diagnostics Limited, Indianapolias, IN, USA) had as high a sensitivity and specificity as the ddPCR system.[@b19-ott-10-3307] However, our T790M rate was not the lowest one, either in all the patient receiving blood biopsy or in patients confirmed by tissue biopsy. In contrast, a clinical trial[@b7-ott-10-3307] reported the lowest T790M rate in both two situations. These results indicate that the less sensitive, conventional ARMS used in the present study does not necessarily perform worse than the sequencing techniques used in other studies. This implies that technology is not the primary reason why the T790M rate of ctDNA sequencing is highly varied.

While some authors have suggested the need to optimize the timing of blood biopsy,[@b24-ott-10-3307] this seems unlikely to explain the higher T790M rate, since in the present study and four other prospective studies,[@b6-ott-10-3307]--[@b8-ott-10-3307],[@b23-ott-10-3307] both blood and tissue biopsies were performed at the same time after disease progression. It seems more likely that the higher T790M rate obtained with conventional ARMS is due to high ctDNA levels; in fact, high levels of circulating free DNA are associated with poor prognosis.[@b25-ott-10-3307],[@b26-ott-10-3307] This implies that the risk of false negatives is much higher with blood biopsy than tissue biopsy in patients with good prognosis. We do not know whether the poor prognosis causes the high ctDNA levels in the present study. However, we do know that the disease course of patients in the clinical trial (mentioned earlier),[@b7-ott-10-3307] who only received first-line EGFR TKI treatment, is shorter compared to patients who received a multiline treatment in real-world studies. We believe the factors causing high ctDNA levels are intrinsically connected with clinical features, different from those factors relating to preanalytical plasma processing and ctDNA extraction or detection technique,[@b10-ott-10-3307] and cannot be controlled through technological optimization.[@b10-ott-10-3307] It is necessary to find out what these factors are, so that patients with high ctDNA levels can be identified to choose blood biopsy as preferred diagnostic approach. In the meantime, and even more importantly, it may be advisable to use tissue biopsy for patients with low ctDNA levels in order to avoid the risk of false-negative by blood biopsy.

Future work should attempt to identify the clinical features relating to ctDNA level as well as additional factors that may affect the sensitivity and specificity of blood biopsy in order to clarify for which patients and at what times in disease progression this type of biopsy can be reliably performed. At the same time, studies should continue to examine how to make re-biopsy as safe as possible, especially since some patients, such as those with low ctDNA levels, may not be suitable for blood biopsy.

Supplementary material
======================

###### 

Characteristics of the studies

  Characteristics            Sundaresan et al[@b27-ott-10-3307]   Yanagita et al[@b28-ott-10-3307]   Takahama et al[@b29-ott-10-3307]   Mok et al[@b30-ott-10-3307]   Our research
  -------------------------- ------------------------------------ ---------------------------------- ---------------------------------- ----------------------------- ---------------
  Type                       Prospective                          Prospective                        Prospective                        Prospective                   Prospective
  Enrolling condition        Real world                           Clinical trial                     Real world                         Real world                    Real world
  Patient feature            AR                                   AR                                 AR                                 AR                            AR
  Sequencing method                                                                                                                                                   
   Tissue                    IS                                   ddPCR                              ddPCR                              Cobas^®^ (ASA)                AmoyDx (ARMS)
   Plasma ctDNA              AS PCR                               ddPCR                              ddPCR                              Cobas^®^ version 2 (ASA)      AmoyDx (ARMS)
  Positive rate of T790M                                                                                                                                              
   In all the patients (%)   50.0                                 23.0                               28.8                               52.5                          25.0--37.5
   In patients CTB (%)       60.0                                 33.3                               64.5                               52.5                          41.2

**Abbreviations:** AR, acquired resistance; IS, institution's standard; ASA, allele-specific amplification; AS PCR, allele-specific PCR; ddPCR, droplet digital-PCR; ARMS, amplification refractory mutation system; CTB, confirmed by tissue biopsy.
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**Abbreviation:** ctDNA, circulating tumor DNA.](ott-10-3307Fig1){#f1-ott-10-3307}

![Comparison of *EGFR* mutation status based on tissue biopsy or plasma ctDNA with respect to (**A**) exon 19 deletion, (**B**) L858R mutation, or (**C**) T790M mutation.\
**Abbreviation:** ctDNA, circulating tumor DNA.](ott-10-3307Fig2){#f2-ott-10-3307}

###### 

Patient characteristics

  Characteristics                   N (%)
  --------------------------------- -----------
  Age, years                        
   Median                           53.2
   Range                            36--75
  Sex                               
   Male                             23 (51.1)
   Female                           22 (48.9)
  Histology (initial biopsy)        
   Adenocarcinoma                   42 (93.3)
   Squamous carcinoma               3 (6.7)
   Other                            0 (0.0)
  Stage before re-biopsy            
   IIIB                             2 (4.4)
   IV                               43 (95.6)
  Type of initial *EGFR* mutation   
   19 Del                           30 (66.7)
   L858R                            15 (33.3)
   Other                            0 (0.0)
  Type of initial EGFR TKI          
   Gefitinib                        37 (82.2)
   Erlotinib                        4 (8.9)
   Icotinib                         4 (8.9)
  Line of initial EGFR TKI          
   First                            39 (86.7)
   Second                           6 (13.3)
  Response to initial EFGR TKI      
   CR/PR/SD                         43 (93.3)
   PD                               2 (6.7)
  Second biopsy                     
   Tissue biopsy                    38 (84.4)
   Blood biopsy                     31 (68.9)
   Both                             24 (53.3)

**Abbreviations:** EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; CR, complete response; PR, partial response; SD, stable disease; PD progressive disease.

###### 

*EGFR* genotyping of initial and secondary biopsy

  *EGFR* genotyping                                             Initial     Secondary   
  ------------------------------------------------------------- ----------- ----------- -----------
  Exon 19 deletion                                              30 (66.7)   28 (73.7)   12 (38.7)
  L858R                                                         15 (33.3)   11 (28.9)   6 (19.4)
  T790M                                                                                 
   Weakly positive[a](#tfn2-ott-10-3307){ref-type="table-fn"}   0 (0.0)     0 (0.0)     4 (12.9)
   Positive                                                     0 (0.0)     26 (68.4)   9 (29.0)
  S768I                                                         0 (0.0)     0 (0.0)     2 (6.5)
  Negative                                                      0 (0.0)     0 (0.0)     12 (38.7)

**Note:**

The curve rises up, but does not reach the peak.

**Abbreviation:** ctDNA, circulating tumor DNA.

###### 

*EGFR* genotyping in patients who received both tissue and plasma ctDNA tests

  *EGFR* genotyping                                             Initial     Secondary   
  ------------------------------------------------------------- ----------- ----------- -----------
  Exon 19 deletion                                              16 (66.7)   18 (75.0)   10 (41.7)
  L858R                                                         8 (33.3)    7 (29.2)    4 (16.7)
  T790M                                                                                 
   Weakly positive[a](#tfn4-ott-10-3307){ref-type="table-fn"}   0 (0.0)     0 (0.0)     3 (12.5)
   Positive                                                     0 (0.0)     17 (70.8)   6 (25.0)
  S768I                                                         0 (0.0)     0 (0.0)     2 (8.3)
  Negative                                                      0 (0.0)     0 (0.0)     9 (37.5)

**Note:**

The curve rises up, but does not reach the peak.

**Abbreviation:** ctDNA, circulating tumor DNA.

###### 

T790M mutation tested by both tumor tissue and plasma ctDNA levels

  Tissue biopsy   Plasma ctDNA   
  --------------- -------------- ----
   Positive       7              10
   Negative       2              5

**Abbreviation:** ctDNA, circulating tumor DNA.
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